← Back to Search

Other

Acupuncture for High Blood Pressure

N/A
Recruiting
Led By Shaista Malik
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically diagnosed with mild to moderate hypertension and NOT on medication (Office SBP > 140 mmHg and < 160 mmHg Or ABPM average SBP > 130 mmHg and < 145 mmHg)
No significant ECG change reflecting ischemia (i.e. ST elevation or depression) at rest will be recruited to participate in this study.
Must not have
Subjects will be excluded if they have coronary disease (by history or on ECG screening), conduction abnormalities on ECG consistent with left bundle branch block, cardiac arrhythmias associated with low blood pressure (<90 mmHg), peripheral vascular disease, orthopedic disease, diabetic neuropathy or severe hypertension (BP >170 mmHg systolic or >110 mmHg diastolic), or any other physical or psychological illness
Subjects will be excluded if on anti-hypertensive medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 4.5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a treatment involving small electrical currents through needles to help people with mild to moderate high blood pressure who are not taking medication. The treatment aims to reduce stress and inflammation, which can help lower blood pressure.

Who is the study for?
This trial is for people aged 50-75 with mild to moderate high blood pressure who aren't taking any hypertension medication. Participants should have a stable ECG without signs of ischemia. Pregnant or nursing individuals, those sensitive to topical preparations, on anti-hypertensive drugs, or with certain heart conditions and severe illnesses are excluded.
What is being tested?
The study tests if electroacupuncture can lower blood pressure in patients not using hypertension meds. It's an 8-week course with sessions once weekly, aiming to see how effective this therapy is for controlling high blood pressure without medication.
What are the potential side effects?
Potential side effects may include minor bruising at needle sites, light-headedness after treatment, rare allergic reactions to needles or materials used during acupuncture, and discomfort during the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have high blood pressure but am not taking medication for it.
Select...
My heart's electrical activity is normal, with no signs of blockage.
Select...
I have high blood pressure but am not taking medication for it.
Select...
I am between 50 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have heart disease, severe high blood pressure, or other serious health issues.
Select...
I am not taking any blood pressure medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 4.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 4.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in sympathetic and parasympathetic nervous systems
Secondary study objectives
Change in biomarkers like cytokines
Other study objectives
Change in blood pressure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Sympathoinhibitory EA (SI-EA)Experimental Treatment1 Intervention
sympatho-inhibitory electroacupuncture therapy
Group II: Control EA (Sham-EA)Experimental Treatment1 Intervention
Sham electroacupuncture
Group III: Combined EA (cEA)Experimental Treatment1 Intervention
combination of SI-EA and AI-EA
Group IV: Anti-inflammatory EA (AI-EA)Experimental Treatment1 Intervention
Anti-inflammatory electroacupuncture therapy

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for high blood pressure include medications such as ACE inhibitors, beta-blockers, diuretics, and calcium channel blockers, as well as non-pharmacologic interventions like lifestyle changes and acupuncture. ACE inhibitors work by blocking the formation of a hormone that narrows blood vessels, beta-blockers reduce heart rate and the heart's output of blood, diuretics help the kidneys remove excess sodium and water, and calcium channel blockers relax blood vessels by preventing calcium from entering cells of the heart and blood vessel walls. Acupuncture, as studied in trials, may reduce blood pressure by modulating the autonomic nervous system, leading to vasodilation and subsequent blood pressure reduction. Understanding these mechanisms is crucial for patients as it helps them make informed decisions about their treatment options and manage their condition more effectively.

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
564 Previous Clinical Trials
1,932,476 Total Patients Enrolled
Shaista MalikPrincipal InvestigatorUniversity of California, Irvine

Media Library

Electroacupuncture (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05530512 — N/A
High blood pressure Research Study Groups: Combined EA (cEA), Sympathoinhibitory EA (SI-EA), Control EA (Sham-EA), Anti-inflammatory EA (AI-EA)
High blood pressure Clinical Trial 2023: Electroacupuncture Highlights & Side Effects. Trial Name: NCT05530512 — N/A
Electroacupuncture (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05530512 — N/A
High blood pressure Patient Testimony for trial: Trial Name: NCT05530512 — N/A
~51 spots leftby Mar 2026